Tenaya Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $68.6M | $86.7M | $98.0M | $94.5M | $54.4M |
| Operating expenses | $93.3M | $115.9M | $131.2M | $125.6M | $72.8M |
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M |
| Pretax income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M |
| Balance Sheet | |||||
| Cash and equivalents | $100.5M | $4.3M | $45.7M | $95.3M | $38.1M |
| Current assets | $105.6M | $67.4M | $111.6M | $193.8M | $255.4M |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M |
| Current liabilities | $15.4M | $16.0M | $22.7M | $24.2M | $21.8M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M |
| Stockholders' equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M |
| Cash Flow Statement | |||||
| Cash from operations | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M |
| Depreciation and amortization | $8.4M | $8.5M | $8.7M | $6.5M | $3.0M |
| Stock-based compensation | $13.0M | $16.5M | $15.3M | $11.5M | $3.0M |
| Capital expenditure | $618,000 | $1.0M | $1.2M | $20.6M | $25.1M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M | -$85.9M |
| Share repurchases | — | — | — | — | $13,000 |
Shares outstanding 217.0M · Free float 69.3%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.